

[New Drug Approvals](#)

Generic Name (Trade Name—Company)

February 12, 2018

Bictegravir/emtricitabine/tenofovir alafenamide

(Biktarvy—Gilead Sciences)

**Once-daily, single-tablet regimen approved for
treatment of HIV-1 infection in adults**

Uses/Notes

[Gilead Sciences announced](#) FDA approval of bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg ([BIC/FTC/TAF] Biktarvy—Gilead), a once-daily, single-tablet regimen (STR) for treatment of HIV-1 infection in adults who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA

Source URL:

<http://aphanet.org/new-drug-approvals/once-daily-single-tablet-regimen-approved-treatment-hiv-1-infection-adults>

APhA DrugInfoLine is an official publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in APhA DrugInfoLine do not necessarily represent the policy, recommendations, or endorsement of APhA. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that information contained in APhA DrugInfoLine is accurate and current; however, they shall have no liability to any person or entity with regard to claims, losses, or damages caused or alleged to be caused, directly or indirectly, by use of any information contained in the publication. All decisions about drug therapy must be based on the independent judgment of the clinician. Copyright © 2000–2011, American Pharmacists Association. All rights reserved.